Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basmisanil in severe motor impairment post-ischemic stroke
NCT02928393Phase 2Terminated
- Sponsor
- Roche
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Basmisanil with Placebo (2 arms). Primary endpoint: Fugl-Meyer Motor Scale at 90 days. Started Feb 2017; status: terminated.
02
Drugs
basmisanil
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02928393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928393.